Tanshinone-IIA mediated neuroprotection by modulating neuronal pathways

Sherawat, Kajal; Mehan, Sidharth

doi:10.1007/s00210-023-02476-8

Cited by 9 publications

(1 citation statement)

References 169 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was also observed that SCU-PLGA NPs greatly extended the release curve and blood circulation duration of SCU, as well as preventing nerve cell apoptosis, as shown in Figure 4 . TanIIA (tanshinone IIA) possesses multiple pharmacological properties, including antioxidant, anti-inflammatory, and autoimmune regulation [ 97 , 98 , 99 ]. However, it is poorly soluble and has a short half-life.…”

Section: Applications Of Plga-based Nanostructures In Drug Delivery A...mentioning

confidence: 99%

The Recent Applications of PLGA-Based Nanostructures for Ischemic Stroke

Yan,

Huang,

Feng

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

With the accelerated development of nanotechnology in recent years, nanomaterials have become increasingly prevalent in the medical field. The poly (lactic acid–glycolic acid) copolymer (PLGA) is one of the most commonly used biodegradable polymers. It is biocompatible and can be fabricated into various nanostructures, depending on requirements. Ischemic stroke is a common, disabling, and fatal illness that burdens society. There is a need for further improvement in the diagnosis and treatment of this disease. PLGA-based nanostructures can facilitate therapeutic compounds’ passage through the physicochemical barrier. They further provide both sustained and controlled release of therapeutic compounds when loaded with drugs for the treatment of ischemic stroke. The clinical significance and potential of PLGA-based nanostructures can also be seen in their applications in cell transplantation and imaging diagnostics of ischemic stroke. This paper summarizes the synthesis and properties of PLGA and reviews in detail the recent applications of PLGA-based nanostructures for drug delivery, disease therapy, cell transplantation, and the imaging diagnosis of ischemic stroke.

show abstract

Section: Applications Of Plga-based Nanostructures In Drug Delivery A...mentioning

confidence: 99%

The Recent Applications of PLGA-Based Nanostructures for Ischemic Stroke

Yan,

Huang,

Feng

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

show abstract

Chitosan-coated nanostructured lipid carriers for effective brain delivery of Tanshinone IIA in Parkinson’s disease: interplay between nuclear factor-kappa β and cathepsin B

Hassan,

El-Kamel,

Allam

et al. 2023

Drug Deliv. and Transl. Res.

View full text Add to dashboard Cite

Parkinson’s disease (PD) is the second most common progressive neurodegenerative disorder associated with increased oxidative stress, the underlying vital process contributing to cell death. Tanshinone IIA (TAN) is a phytomedicine with a documented activity in treating many CNS disorders, particularly PD owing to its unique anti-inflammatory and antioxidant effect. However, its clinical utility is limited by its poor aqueous solubility, short half-life, and hence low concentration reaching targeted cells. This work aimed to develop a biocompatible chitosan-coated nanostructured lipid carriers (CS-NLCs) for effective brain delivery of TAN for PD management. The proposed nanosystem was successfully prepared using a simple melt-emulsification ultra-sonication method, optimized and characterized both in vitro and in vivo in a rotenone-induced PD rat model. The developed TAN-loaded CS-NLCs (CS-TAN-NLCs) showed good colloidal properties (size ≤ 200 nm, PDI ≤ 0.2, and ζ-potential + 20 mV) and high drug entrapment efficiency (> 97%) with sustained release profile for 24 h. Following intranasal administration, CS-TAN-NLCs succeeded to achieve a remarkable antiparkinsonian and antidepressant effect in diseased animals compared to both the uncoated TAN-NLCs and free TAN suspension as evidenced by the conducted behavioral tests and improved histopathological findings. Furthermore, biochemical evaluation of oxidative stress along with inflammatory markers, nuclear factor-kabba β (NF-Kβ) and cathepsin B further confirmed the potential of the CS-TAN-NLCs in enhancing brain delivery and hence the therapeutic effect of TAN of treatment of PD. Accordingly, CS-TAN-NLCs could be addressed as a promising nano-platform for the effective management of PD. Graphical abstract

show abstract

Tanshinone IIA inhibited intermittent hypoxia induced neuronal injury through promoting autophagy via AMPK-mTOR signaling pathway

Liu

et al. 2023

Journal of Ethnopharmacology

View full text Add to dashboard Cite

Tanshinone-IIA mediated neuroprotection by modulating neuronal pathways

Cited by 9 publications

References 169 publications

The Recent Applications of PLGA-Based Nanostructures for Ischemic Stroke

The Recent Applications of PLGA-Based Nanostructures for Ischemic Stroke

Chitosan-coated nanostructured lipid carriers for effective brain delivery of Tanshinone IIA in Parkinson’s disease: interplay between nuclear factor-kappa β and cathepsin B

Tanshinone IIA inhibited intermittent hypoxia induced neuronal injury through promoting autophagy via AMPK-mTOR signaling pathway

Contact Info

Product

Resources

About